Loading....
Coupon Accepted Successfully!

Pharmacology

Open Flashcards

AIIMS Exam Questions

Question
6 out of 15
 

All are true about rituximab except

 

 
A Chimeric anti-CD20 monoclonal antibody
B Infusion reactions
C Myelosuppression and alopecia
D Dose independent pharmacokinetics
Ans. C Myelosuppresion and alopecia

Rituximab

  • Rituximab is a chimeric monoclonal antibody against CD 20, expressed in 90% of B cell neoplasms.
  • It is approved for treatment of CLL, Lymphomas, Waldenstorm macroglobilinemia. Nonneoplastic uses are TTP, autoimmune hemolytic anemia, cryoglobulinemia, rheumatoid arthritis and multiple sclerosis.
  • Most important sideeffect is infusion reaction characterized by hypersensitivity associated with fever, chills and hypotension. It can cause reactivation of hepatitis C and JC virus.
  • It follows dose independent kinetics. The half life is 22 days and is given by I/V route once weekly for 4 weeks followed by maintenance dose every 3-6 months.

Other anti CD 20 monoclonal antibodies

  • Ofatumumab – Used for treatment of CLL refractory to Fludarabine and Alemtuzumab.
  • Ocrelizumab – Approved in 2013 for treatment of rheumatoid arthritis.

AIIMS Exam Questions Flashcard List

15 flashcards
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
13)
14)
15)